9 Meters Biopharma, Inc.

NMTRCIK 0001551986 · Every Form 4 filed by insiders at this issuer. See financials →

Annual report (10-K)

Latest 10-K/A filed Apr 28, 2023. Sentiment + YoY language diff vs prior year. Read sections →

Signal:NeutralFull-doc fallback

Full filing:tone 0.0019

Sentiment via Loughran-McDonald lexicon · YoY diff via Jaccard similarity + paragraph set difference.

YoY shift: Unscored

Year-over-year tone shift - average net-tone change across Risk Factors and MD&A vs the prior 10-K.

Why YoY instead of absolute: the LM lexicon has ~6.6× more negative words than positive (legal/risk-disclosure language is heavy on hedging), so every 10-K reads bearish on raw tone. Year-over-year change strips that bias and surfaces the actual shift in management's framing.

Per-snippet highlights

Sentence-level sentiment highlighting with category and subcategory filters is coming once the snippet-scoring pipeline lands. For now, dig into the actual section text on the Sections tab.

Top insiders

Most active reporters at 9 Meters Biopharma, Inc.

Name	Roles	Filings
Rice Yehuda Michael	Director	2
Ventimiglia Samantha	Director	2

Showing 6-7 of 7

Per pagePrevPage 2 of 2

All filings

21 Form 4 / 4-A filings, newest first

Filed	Insider	Top transaction	Shares	Price	Value
Mar 31, 2023	Sirgo Mark A Director	AGrant	7,885	-	-
Mar 29, 2023	Temperato John Chief Executive Officer · Director	AGrant	68,815	-	-
Mar 29, 2023	Sensenig Bethany Chief Financial Officer	AGrant	50,177	-	-
Jun 23, 2022	Constantino Michael T. Director	Holdings only	-	-	-
Jun 23, 2022	Johnson Lorin K Director	Holdings only	-	-	-

Showing 6-10 of 21

Per pagePrevPage 2 of 5Next

Real-time Form 4 intelligence. Smarter insider tracking.

Filed		Top transaction	Shares	Price	Value